Purpose: We compared the markers of bone metabolism – osteocalcin (OC), beta-carboxyterminal cross-linked telopeptide of type I collagen (ß-CrossLaps, ß-CTx) and tumour marker – human epididymis protein 4 (HE4) in the serum with finding during the entry examination and the check-up of whole-body bone scintigraphy of the patient with a malignant melanoma. Methods: Serum concentrations of HE4, OC, ß-CTx were determined in 1 patient (female, age 64 years) with malignant melanoma and correlated with the presence of equivocal bone metastases detected by whole-body bone scintigraphy (the entry examination and check-up after 6 months). Results: The level of markers in the serum of the patient with a malignant melanoma after the first entry examination of the whole-body bone scintigraphy was HE4: 55.33 pmol/l, OC: 25.22 ng/ml, ß-CTx: 0.513 ng/ml and the concentrations of markers after the second check-up were HE4: 67.76 pmol/l, OC: 17.99 ng/ml, ß-CTx: 0.321 ng/ml. We observed progress in bone metastases. Conclusion: The change of the markers levels in the serum (the moderate increase of the level of HE4 and the reduction of the level of the markers of bone metabolism – OC and ß-CTx) during the entry examination and the check-up of the whole-body bone scintigraphy with equivocal finding of bone metastases could be a sign of a possible initiating progression of malignant melanoma despite a clinically negative finding that does not prove the progression of the disease.